Sample size (n) |
1237 |
632 |
107 |
498 |
|
Age (mean, SD) |
|
41.2 (19.1) |
42.0
(19.4) |
39.9 (18.9) |
0.39 |
Gender |
|
|
|
|
0.001 |
Male (n,%) |
521 (42%) |
296 (47%) |
44 (41%) |
181 (36%) |
|
Female (n,%) |
716 (58%) |
336 (53%) |
63 (59%) |
317 (64%) |
|
Race |
|
|
|
|
0.46 |
American Indian/Alaska Native (n,%) |
5 (0.4%) |
1 (0.0001%) |
0
(0%) |
4 (1%) |
|
Asian (n,%) |
216 (17%) |
126 (20%) |
21 (20%) |
69 (14%) |
|
Black or African American (n,%) |
205 (17%) |
102 (16%) |
18
(17%) |
85 (17%) |
|
Mixed race (n,%) |
40 (3%) |
21 (3%) |
3 (3%) |
16 (3%) |
|
Native Hawaiian/Other Pacific Islander (n,%) |
4 (0.3%) |
2
(0.0001%) |
0 (0%) |
2 (0.0001%) |
|
Unknown (n,%) |
95 (8%) |
44 (7%) |
7 (7%) |
44 (9%) |
|
White (n,%) |
672 (54%) |
336 (53%) |
58 (54%) |
278 (56%) |
|
Comorbidities |
|
|
|
|
|
Hypertension |
|
115 (18%) |
20 (19%) |
72 (14%) |
0.21 |
Diabetes |
|
37 (6%) |
7 (7%) |
26 (5%) |
0.78 |
Asthma |
|
250 (40%) |
38 (36%) |
169 (34%) |
0.16 |
Obesity (BMI>30) |
|
112 (20%) |
14 (16%) |
85
(19%) |
0.61 |
Other medications |
|
|
|
|
|
ACEi |
|
20 (3%) |
4 (4%) |
8 (2%) |
0.16 |
COVID-19 infection |
|
|
|
|
|
Laboratory confirmed COVID-19 infection |
87 (7%) |
39
(6%) |
11 (10%) |
37 (7%) |
0.26 |